DDInter460 DDInter1376
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Cytarabine {u} (Compound) resembles {v} (Compound) Regadenoson
Cytarabine {u} (Compound) resembles {v} (Compound) Nelarabine
Cytarabine {u} (Compound) treats {v} (Disease) hematologic cancer
Cytarabine {u} (Compound) binds {v} (Gene) POLB
Cytarabine {u} (Compound) upregulates {v} (Gene) TICAM1
Cytarabine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleic Acid Synthesis Inhibitors
Cytarabine {u} (Compound) downregulates {v} (Gene) KIF4A
Cytarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Cytarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Cytarabine (Compound) resembles Regadenoson (Compound)
Cytarabine (Compound) resembles Nelarabine (Compound)
Cytarabine (Compound) treats hematologic cancer (Disease)
Cytarabine (Compound) binds POLB (Gene)
Cytarabine (Compound) upregulates TICAM1 (Gene)
Cytarabine (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class)
Cytarabine (Compound) downregulates KIF4A (Gene)
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin